Incruse®

BRONCHODILATORS

LONG-ACTING MUSCARINIC ANTAGONIST (LAMA)

  • Class

    • Long-acting muscarinic antagonist (LAMA)

  • Active ingredient

    • Umeclidinium (as bromide)

  • Device

  • Age

    • 18 +
  • Typical use

    • Asthma (off-label)
      in addition to a high dose ICS + LABA when uncontrolled

    Asthma management principles
    • COPD
      initial treatment or in addition to a LABA when uncontrolled 

    COPD management principles
  • Marketed strength

    • 62.5 mcg
  • Number of doses

    • 30 doses
  • Dose indicator

    • Yes | Numerical
  • Usual adult dosage

    • 1 inh QD

  • Usual pediatric dosage

    • -

  • Required inspiratory flow

    • > 30 - 60 L/min
      Medium-low internal resistance (R2)

    Inspiratory flows
  • Public coverage

    • AB – BC – MN – NIHB – ON – QC – YT | Open/Regular Benefit
      NB – NL – NS – PEI – SK | Restricted Benefit with criteria 

    Provincial coverage criteria
  • Advantages

    • Easy handling
    • Precise dose counter
  • Disadvantages

    • Taste that can be unpleasant
    • Lip sealing difficult for some older patients
    Side effects

Product monograph

Download

Search for other inhalers